Twenty-two subjects (11 women and 11 men) were included in the reproducibility study and consisted of 19 healthy volunteers and 3 patients with evidence of coronary artery disease (CAD). All subjects were admitted twice to the Nuclear Medicine Division of the Radiology Department at the Brigham and Women's Hospital within a two-week interval and underwent repeated rest/stress studies. At each visit, they were injected with 50 mCi of 82Rb and imaged dynamically for 6 minutes at rest and during dipyridamole stress (IV infusion of 0.142 mg/kg/min for 4 min, max 60 mg). Following an overnight fast and a 24-hour cessation of all caffeine- or methylxanthine-containing substances, subjects were scanned in 2D mode on a whole body PET-CT scanner with BGO detectors (Discovery ST Lightspeed 64, General Electric Healthcare, Milwaukee, WI). First, a scout CT acquisition (120 kVp, 10 mA) was performed to ensure proper patient positioning, then a CT transmission scan was acquired (140 kVp, 20 mA) for subsequent attenuation correction. Beginning at the time of intravenous (i.v.) bolus administration of 50 mCi (1850 MBq) of 82Rb (Bracco Diagnostics, Princeton, NJ) in 14±6 mL of saline, twenty seven dynamic PET frames were acquired over six minutes as follows: fourteen 5-sec acquisitions were first performed, followed by six 10-sec acquisitions, three 20-sec acquisitions, three 30-sec acquisitions and finally, one 90-sec acquisition. The initial fast frames were used to capture the rapid wash-in and wash-out of 82Rb from the left and right ventricular cavities. Immediately after completion of the rest study, a standard i.v. dipyridamole infusion (0.142 mg/kg/min) was performed for 4 minutes. Three minutes after termination of the dipyridamole infusion, a second dose of 50 mCi (1850 MBq) of 82Rb was injected and dynamic PET frames acquired in the same fashion. A second CT transmission scan (140 kVp, 20 mA) was then acquired for attenuation correction of the stress images. The heart rate, systemic blood pressure, and 12-lead ECG were recorded at baseline and throughout the infusion of dipyridamole. The rate pressure product was calculated as heart rate multiplied by systolic blood pressure. Hemodynamic data are summarized in Table 1.